November 22, 2017 12:29 PM ET

Pharmaceuticals

Company Overview of Ora, Inc.

Company Overview

Ora, Inc. provides clinical research and drug development services. The company offers pre-clinical research, animal toxicology studies, and compounds identification and procurement services. Additionally, it provides clinical consulting, data management, statistical analysis, and medical writing services. The company also offers strategic planning, speaker training, media planning and placement, and public relations services. Ora, Inc., formerly known as Ophthalmic Research Associates, Inc., is based in Andover, Massachusetts.

300 Brickstone Square

Andover, MA 01810

United States

Founded in 1985

Phone:

978-685-8900

Fax:

978-689-0020

Key Executives for Ora, Inc.

Chief Executive Officer and President
Senior Vice President and Chief Operating Officer
Chief Medical Officer and Senior Vice President
Vice President of Business Development
Director of Allergy Research
Compensation as of Fiscal Year 2017.

Ora, Inc. Key Developments

Ora, Inc. Appoints Lori Helgeson as its Senior Director of Clinical Operations

Ora, Inc. announced that it has appointed Lori Helgeson as the Senior Director of Clinical Operations. Lori will lead a global staff of experienced ophthalmology project managers and will oversee the planning and execution of the company's clinical operations across several key therapeutic areas including retina, glaucoma, inflammation, and infection, among others. Lori joins the company from INC Research, where she served as Senior Project Director in ophthalmology, providing senior level oversight to the global ophthalmology study teams and ensuring quality project execution.

AXIM Biotech Retains Ora, Inc. to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications

AXIM®Biotechnologies Inc. announced that it has retained the services of Ora® Inc., to perform the company’s upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics.

Okogen, Inc. Secures Ora, Inc. to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis

Okogen, Inc. has secured Ora, Inc. to conduct the clinical studies and lead the regulatory strategy of OKG-0301 for the treatment of adenoviral conjunctivitis. OKG-0301, Okogen's lead candidate, is an ophthalmic formulation of a potent ribonuclease with broad-spectrum antiviral properties. Adenoviral conjunctivitis is the primary cause of eye infections globally, lasting typically 2-3 weeks. In a clinically predictive rabbit model of adenoviral conjunctivitis, OKG-0301 significantly reduced viral titers of infected eyes in addition to shortening the duration of viral shedding compared to controls. OKG-0301 demonstrated a clear dose-dependent response, enabling predictive optimization of ongoing dosing protocols.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ora, Inc., please visit www.oraclinical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.